Skye Bioscience (SKYE)

Its lead metabolic programme is nimacimab, an antibody designed to inhibit peripheral CB1 receptors through negative allosteric modulation. Skye is developing this candidate for obesity, a large and competitive therapeutic area where drug developers are seeking new mechanisms that may complement or differ from existing weight-loss treatments. By focusing on peripheral CB1 activity, the programme is intended to explore potential metabolic benefits while avoiding central nervous system effects associated with some earlier cannabinoid-pathway approaches.

Skye is also developing SBI-100 Ophthalmic Emulsion, a topical eye formulation that acts as a CB1 agonist. This candidate is being studied for glaucoma and ocular hypertension, conditions in which reducing intraocular pressure is central to preserving vision and slowing disease progression. The ophthalmology programme reflects a different use of cannabinoid biology, applying receptor activation locally in the eye rather than systemic receptor inhibition.

As a clinical-stage drug developer, Skye does not have the diversified revenue profile of a commercial pharmaceutical company. Its valuation is closely linked to clinical trial progress, safety and efficacy data, regulatory feedback, financing capacity and the competitive landscape in obesity and ophthalmology. The company is distinctive for building its pipeline around selective modulation of CB1, an established biological target with renewed interest in more precisely engineered therapies.